Research Topics
| R M CarnahanSummaryAffiliation: University of Oklahoma Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Consistency of antidepressant and chronic nonpsychiatric medication use in a high-risk clinical populationRyan M Carnahan
The University of Oklahoma, Department of Pharmacy Clinical and Administrative Sciences, 4502 E 41st St, Suite 2H19, Tulsa, OK 74135 2512, USA
Res Social Adm Pharm 4:367-74. 2008..Although antidepressant persistence has been well described, little is known about consistency patterns...
The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activityRyan M Carnahan
University of Oklahoma College of Pharmacy, Department of Pharmacy, Tulsa, Oklahoma 74315 2512, USA
J Clin Pharmacol 46:1481-6. 2006..This study replicated findings on the association of the ADS with SAA. Future work will determine whether the ADS is clinically useful for preventing anticholinergic adverse effects...
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapyR M Carnahan
Department of Pharmacy Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, OK 74135, USA
Acta Psychiatr Scand 113:135-41. 2006..To determine whether atypical antipsychotic polytherapy is a risk factor for drug treatment for extrapyramidal side-effects (anti-EPS drugs) and whether the risk is attributable to antipsychotic dose...
Acute ethanol intoxication after consumption of hairsprayRyan M Carnahan
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Oklahoma, Tulsa, Oklahoma 74315 2512, USA
Pharmacotherapy 25:1646-50. 2005..The source and its components should be identified as soon as possible in order to assess other potential toxicities...
Ziprasidone, a new atypical antipsychotic drugR M Carnahan
Clinical and Administrative Pharmacy Division, College of Pharmacy, University of Iowa, Iowa City 52242-1112, USA
Pharmacotherapy 21:717-30. 2001..In contrast, ziprasidone has a low propensity for causing weight gain. For patients requiring an antipsychotic drug, ziprasidone represents a new treatment option with a limited adverse effect profile...
Rivastigmine-induced dystoniaClay J Pavlis
Sanford School of Medicine, University of South Dakota USD, Sioux Falls 57110, USA
Am J Health Syst Pharm 64:2468-70. 2007..A case of acute dystonia related to rivastigmine use is reported...
Severe hyperlipidemia associated with olanzapine and quetiapine useRyan M Carnahan
Am J Psychiatry 164:1614-5. 2007
Clozapine-induced leukopenia successfully treated with lithiumEric C Kutscher
College of Pharmacy, South Dakota State University, Sioux Falls, SD 57110, USA
Am J Health Syst Pharm 64:2027-31. 2007..A case of clozapine-induced leukopenia successfully treated with lithium is reported...
Quetiapine for acute mania in bipolar disorderNancy C Brahm
Department of Pharmacy Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy UOCP, Tulsa, OK 74135 2512, USA
Am J Health Syst Pharm 64:1045-53. 2007..The efficacy and tolerability of quetiapine in the treatment of acute mania were reviewed...
The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?Ryan M Carnahan
Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, USA
J Am Geriatr Soc 52:2082-7. 2004..To measure the prevalence of anticholinergic use cross-sectionally in patients receiving cholinesterase inhibitors and to describe change in use of anticholinergics upon inception of cholinesterase inhibitor treatment...
Methodological concerns in a trial of ziprasidone and olanzapineRyan M Carnahan
Am J Psychiatry 162:1391; author reply 1391-2. 2005
A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practiceRyan M Carnahan
University of Iowa, College of Pharmacy, 415 S Pharmacy Building, Iowa City, Iowa 52242-1112, USA
Psychopharmacol Bull 36:24-39. 2002....
Aripiprazole, a novel atypical antipsychotic drugTami R Argo
College of Pharmacy, University of Iowa, Iowa City, Iowa 52242-1112, USA
Pharmacotherapy 24:212-28. 2004..Patients receiving aripiprazole experienced EPS at a rate similar to that seen with placebo. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy...
Hypomania with agitation associated with varenicline use in bipolar II disorderAnne E Morstad
Ann Pharmacother 42:288-9. 2008
The association of weight gain and olanzapine plasma concentrationsPaul J Perry
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
J Clin Psychopharmacol 25:250-4. 2005..The association of weight gain with plasma concentrations during treatment with olanzapine may support the utilization of plasma drug concentration as a marker for antipsychotic-induced weight gain in the treatment of schizophrenia...
